Please use this identifier to cite or link to this item:
http://hdl.handle.net/1843/56584
Type: | Artigo de Periódico |
Title: | Medication persistence for psoriatic arthritis in a Brazilian real-world setting |
Authors: | Michael Ruberson Ribeiro da Silva Jéssica Barreto Ribeiro dos Santos Alessandra Maciel Almeida Alexander Itria Adriana Maria Kakehasi Juliana Alvares Teodoro Francisco de Assis Acurcio |
Abstract: | Aim: To evaluate the persistence of biological (TNF inhibitor [anti-TNF]) and synthetic (conventional syntheticdisease-modifyingantirheumaticdrugs[csDMARDs])antirheumaticagentsforpsoriaticarthritisand their associated factors. Methods: A historical cohort was developed. Persistence and associated factors wereevaluatedat6and12months.Results:Atotalof161patientswereincluded.Theanti-TNFtreatment presented higher persistence as compared with csDMARDs at 6 (83.4 vs 50.8%; p < 0.05) and 12 months (66.4vs35.6%;p<0.05).Fromanti-TNFs,adalimumabandetanerceptpresentedsimilarpersistence,along with leflunomide and methotrexate among the csDMARDs. The factors associated with non-persistence withregardtoanti-TNFagentswerefemalesexanduseofinfliximab.Conclusion:Anti-TNFagentsareimportanttherapeuticalternativesand presentlowerratesofdiscontinuationascomparedwithcsDMARDs. Lay abstract: Conventional synthetic disease-modifying antirheumatic drugs (csDMARD) and anti-TNF agents were included in the Brazilian National Health System in 2009, yet were not previously the target of evaluations in a Brazilian context. Persistence, that is the time between starting and discontinuing the drug, is a proxy of effectiveness and safety for antirheumatic agents. This study evaluated medication persistence and relevant factors associated with it. Patients using infliximab showed a lower medication persistence when compared with adalimumab and etanercept. The medication persistence with anti-TNF agents was higher when compared with csDMARDs. Female sex and infliximab were predictors of medication non-persistence. |
Subject: | Agentes anti-reumaticos Medicamentos |
language: | por |
metadata.dc.publisher.country: | Brasil |
Publisher: | Universidade Federal de Minas Gerais |
Publisher Initials: | UFMG |
metadata.dc.publisher.department: | FAR - DEPARTAMENTO DE FARMÁCIA SOCIAL MED - DEPARTAMENTO DE APARELHO LOCOMOTOR MED - DEPARTAMENTO DE CLÍNICA MÉDICA |
Rights: | Acesso Aberto |
metadata.dc.identifier.doi: | https://doi.org/10.4155/fsoa-2018-0101 |
URI: | http://hdl.handle.net/1843/56584 |
Issue Date: | 2019 |
metadata.dc.url.externa: | https://www.future-science.com/doi/10.4155/fsoa-2018-0101 |
metadata.dc.relation.ispartof: | Future Science OA |
Appears in Collections: | Artigo de Periódico |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Medication persistence for psoriatic arthritis in a Brazilian real-world setting.pdf | 183.85 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.